277 related articles for article (PubMed ID: 37855348)
1. Therapeutic Intervention of Serine Protease Inhibitors against Hepatitis C Virus.
Kamal S; Shahzad A; Rehman K; Tariq K; Akash MSH; Imran M; Assiri MA
Curr Med Chem; 2024; 31(15):2052-2072. PubMed ID: 37855348
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
Ezat AA; Elshemey WM
Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
5. Resistance mutations against HCV protease inhibitors and antiviral drug design.
Shang L; Lin K; Yin Z
Curr Pharm Des; 2014; 20(5):694-703. PubMed ID: 23688081
[TBL] [Abstract][Full Text] [Related]
6. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection.
Chen SH; Tan SL
Curr Med Chem; 2005; 12(20):2317-42. PubMed ID: 16181135
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.
Lin C; Kwong AD; Perni RB
Infect Disord Drug Targets; 2006 Mar; 6(1):3-16. PubMed ID: 16787300
[TBL] [Abstract][Full Text] [Related]
8. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P; Sarrazin C
Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus NS3/4A protease.
Kwong AD; Kim JL; Rao G; Lipovsek D; Raybuck SA
Antiviral Res; 1999 Feb; 41(1):67-84. PubMed ID: 10321580
[TBL] [Abstract][Full Text] [Related]
10. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
Pillaiyar T; Namasivayam V; Manickam M
Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients.
Baesi K; Velayati AA; Ashtiani MF; Fakhredini K; Banifazl M; Larijani MS; Basimi P; Ramezani A
Curr HIV Res; 2021; 19(5):391-397. PubMed ID: 34238162
[TBL] [Abstract][Full Text] [Related]
12. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors.
Romano KP; Ali A; Aydin C; Soumana D; Ozen A; Deveau LM; Silver C; Cao H; Newton A; Petropoulos CJ; Huang W; Schiffer CA
PLoS Pathog; 2012; 8(7):e1002832. PubMed ID: 22910833
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Naturally Occurring Resistance-Associated Variants to NS3/4A Protein Inhibitors, NS5A Protein Inhibitors, and NS5B Polymerase Inhibitors in Patients With Chronic Hepatitis C.
Sun D; Dai M; Shen S; Li C; Yan X
Gene Expr; 2018 Mar; 18(1):63-69. PubMed ID: 29221500
[TBL] [Abstract][Full Text] [Related]
14. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy.
Das D; Pandya M
Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852
[TBL] [Abstract][Full Text] [Related]
15. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus.
Morikawa K; Lange CM; Gouttenoire J; Meylan E; Brass V; Penin F; Moradpour D
J Viral Hepat; 2011 May; 18(5):305-15. PubMed ID: 21470343
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.
Wu S; Kanda T; Nakamoto S; Imazeki F; Yokosuka O
World J Gastroenterol; 2013 Dec; 19(47):8940-8. PubMed ID: 24379619
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
Naggie S; Patel K; McHutchison J
J Antimicrob Chemother; 2010 Oct; 65(10):2063-9. PubMed ID: 20688770
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay.
Hu Z; Hu X; He S; Yim HJ; Xiao J; Swaroop M; Tanega C; Zhang YQ; Yi G; Kao CC; Marugan J; Ferrer M; Zheng W; Southall N; Liang TJ
Antiviral Res; 2015 Dec; 124():20-9. PubMed ID: 26515788
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus NS3 inhibitors: current and future perspectives.
Salam KA; Akimitsu N
Biomed Res Int; 2013; 2013():467869. PubMed ID: 24282816
[TBL] [Abstract][Full Text] [Related]
20. Dissection of two drug-targeted regions of Hepatitis C virus subtype 4a infecting Egyptian patients.
El-Tahan RR; Ghoneim AM; Zaghloul H
Virus Genes; 2020 Oct; 56(5):564-581. PubMed ID: 32572756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
